Spun out of Ben Gurion University, Panacea-ml is disrupting clinical development with its “Explainable AI” platform. We tackle the main causes of trial failures: patient population heterogeneity, poor trial design, and the limits of biostatistics. Together these problems are responsible for more than 85% of trial failures not related to drugs' mechanism of action, resulting in $70 billion annual waste and declining pharma R&D ROI. Panacea-ml's solution enables faster market access for new therapies with actionable predictive insights empowering clinical development and data science teams to de-risk, accelerate, and optimize trial designs. Our cutting-edge SaaS platform driven by our proprietary explainable AI is designed to redefine clinical development as our technology uncovers causal relationships between clinical markers, disease progression, and drug responses. Unlike traditional AI black-box models, Panacea-ml leverages causal discovery theory with its proprietary graphical models to not only predict clinical trials outcomes by to provide transparent, clinically-relevant insights into the ‘why’ behind the outcomes. This unique approach enhances predictive accuracy and enables actionable insights, improving trial success rates and R&D teams’ productivity. We validated our explainable-AI across 8 trials in areas like Diabetes, ALS, rare diseases, and oncology, where we enabled a 30% reduction in participants without compromising statistical power and a 60% increase in patient retention. Our platform also rescued a development program in diabetes after a failed Phase 3 trial. We target the $6B Data Analytics and Design segment of the $50B clinical trial market, focusing on high-failure areas like neurology and immuno-metabolic diseases. Panacea-ml aims to improve patients’ clinical outcomes, enhance their quality of life and accelerate access to life-treating therapies by redefining clinical development and empower pharma with advanced AI-analytic tools.